Study design and baseline disease and mutational profiles. (A) Pretransplant screening and enrollment of patients were conducted in the 28-day period before day −8. Schematic and timeline of events for the phase 1 trial of Ven plus Ven/FluBu2 conditioning chemotherapy, including reviewing criteria to initiate maintenance (after day +28), and starting maintenance therapy with Ven and Aza between days +42 to +90. SC, subcutaneously; DL1, 42-day cycles; DL2, 28-day cycles. (B) Comutation plot of diagnostic mutations amenable to MRD tracking. Columns represent individual patients by study identifier (ID) and rows represent clinical variables or the presence of mutation(s) identified at diagnosis or mutations at screening with VAF of ≥1%. This VAF cutoff is suggestive of a diagnostic mutation, which was not confirmed at diagnosis because of lack of diagnostic sample or technical assay differences. Secondary AML (sAML)-associated genes include the following SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR/L1, and STAG2. MAPK signaling genes included were NRAS, KRAS, FLT3, and PTPN11. "Other" includes mutations in the following genes: JAK2, SETBP1, WT1, MYC, EP300, PRPF8, PPM1D, BRAF, CSF3R, PHF6, and GATA2.